William Blair analyst Tim Lugo maintained a Buy rating on Revance Therapeutics (RVNC) yesterday. The company’s shares closed last Monday at $26.70, close to its 52-week high of $26.97.
According to TipRanks.com, Lugo is a 4-star analyst with an average return of 11.8% and a 46.5% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Collegium Pharmaceutical, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revance Therapeutics with a $32.33 average price target, a 23.6% upside from current levels. In a report issued on January 22, Wells Fargo also maintained a Buy rating on the stock with a $35.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $26.97 and a one-year low of $9.88. Currently, Revance Therapeutics has an average volume of 677.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.
Read More on RVNC: